The Cambridge, UK and Holliston, MA, US-based firm says the product is easy to use. It features an on/off switch that allows the lid to be closed without starting the unit and when the lid is opened, the centrifuge stops automatically.
The three rotors include a 6-place rotor for 1.5ml tubes, a 0.2ml PCR strip rotor, and a 1x3in slide rotor. A maximum speed of 6,000rpm/2,000 x g is perfect for quickly spinning down samples, in micro gel filtration applications and for micro-volume centrifugation, the company says.
John Attwood, director of sales and marketing at Scie-Plas, said: ‘The mini centrifuge has been developed to complement our wide range of electrophoresis reagents, buffers and equipment, from transilluminators and blotting units to gel documentation systems.
‘The new mini centrifuge is a highly versatile sample preparation tool for every laboratory bench.’
Scie-Plas puts a new spin on mini centrifuges
Compact model is fitted with three rotors for bioscience research use
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Taking biologic therapies out of the clinic
Read moreHow larger autoinjectors are changing drug delivery device testing
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?